Indian Prime Minister Narendra Modi visited the Zydus Biotech Park in Ahmedabad and got first hand information on ZycoV-D, a Covid19 vaccine candidate.

Indian PM Modi meets scientists at Zydus Cadila Plant in Ahmedabad

PM Modi reached at Bharat Biotech in Hyderabad to review the ongoing preparations for the corona vaccine named as 'Covaxin'.

PM Modi reviews COVID vaccine progress in Hyderabad, Pune and Ahmedabad

India's Prime Minister Narendra Modi has embarked on a visit to review the vaccine development in the country. PM Modi will be visiting 3 top vaccine production hubs in three different cities all in a span of a day.

News Alert: Indian PM Modi to visit top 3 drug makers to review vaccine development

Berlin aims to open six centres with the capacity to vaccinate up to 4,000 people per day with an approved COVID-19 vaccine by mid-December.

Berlin aims to open six vast COVID-19 vaccination centres

The world is desperately waiting for the Corona vaccine, but citizens in Sweden are extremely sceptical. The reason is the bitter experience of the last mass vaccination drive. WION brings you a report.

Survey: 56% Swedes unsure about Corona vaccine

Astra and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.

Astrazeneca likely to run additional global covid-19 vaccine trial

With COVID-19 vaccines in their final stage and results being announced, there are eminent challenges of distributions that still remain. Among the many hurdles, the most crucial is the storage of the vaccines. Pfizer's COVID-19 vaccine needs to be stored in minus 70 degrees for which specialised cold storage units are needed. Germany's Binder, which makes specialized cooling equipment for laboratories has ramped up production of refrigerated containers needed to transport the vaccines.

COVID-19 Vaccine: Race to procure ultra-cold storage

India is making plans to inoculate millions in 2021. According to a report, 250-300 million citizens could get a shot by July 2021. WION's Molly Gambhir tells you more.

Gravitas: Here is how India could distribute its vaccines

The makers of the Oxford vaccine want to sell their shot at cost price to developing countries. How are other vaccine makers planning to price their vaccines? WION's Molly Gambhir has the details.

Gravitas: Will the Oxford shot be the cheapest available vaccine?

As countries compete in the vaccine race, they are all leaning on India for the vaccine supplies. India holds the key to vaccine manufacturing - and unlike some countries, India is not prioritising profit over the health of billions. WION's Molly Gambhir has the details.

Gravitas: Wuhan Vaccine: The World turns to India

Which vaccine candidates are frontrunners? When will you be able to take a shot? Do the vaccines work for everyone? How long does the immunity last? Will the vaccines have any long-term side effects? WION's Molly Gambhir answers some frequently asked questions on vaccines.

Gravitas: Vaccine FAQs: Your every question answered

The US Food & Drugs Administration (FDA) advisors will meet on the December 10 to discuss whether to authorise the Pfizer COVID-19 vaccine for emergency use. The advisory committee will discuss the safety & effectiveness of the vaccine candidate.

FDA panel to discuss Pfizer vaccine on December 10

While the news of potential vaccines is great, vaccination alone will not be able to end the Wuhan Virus Pandemic. Molly Gambhir tells you why.

 Gravitas: Wuhan Virus, a vaccine is not a silver bullet

The good news on vaccines has been welcomed by the markets with open arms. Vaccine progress pushed the global stock market value to a record $95 trillion. Molly Gambhir tells you more.

Gravitas: Vaccine progress pushes the global stock market value to $95 Trillion

1 in 5 Indians may get Wuhan Virus Vaccine by July 2021. Which vaccine will it be? Which vaccines are currently being tested in India? Which vaccines has India pre-ordered?

Gravitas: 1 in 5 Indians could get a vaccine by 2021

India's wait for COVID-19 vaccine is soon to be over. The Indian Health Minister Harsh Vardhan has announced that India is set to get the much waited COVID-19 vaccine early next year.

India will get COVID-19 vaccine by early 2021: Harsh Vardhan

The vaccine candidates from Moderna and Pfizer are the front runners in the vaccine race. When will these vaccines be rolled out? When will India get a vaccine?

Gravitas: The two front runners in the vaccine race

Will the World have a vaccine in December? In another breakthrough, Moderna says its Wuhan virus Vaccine is 94% effective. Who will get it first?

Gravitas: The Wuhan Virus Vaccine race

Trump's covid vaccine announcement was made during the presidential debate with Democratic challenger Joe Biden for the final time before the elections.

Covid vaccine ready and expected within weeks, claims Trump

Several countries are now engaged in initiatives aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines.

Older adults may be most vulnerable to the coronavirus, but ending the pandemic will require vaccinating children, too.

Last week, Pfizer Inc. received permission to test its vaccine in U.S. kids as young as 12, one of only a handful of attempts around the world to start exploring if any experimental shots being pushed for adults also can protect children.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-hunt-for-a-vaccine-the-hefty-cost-for-cutting-corners-337263/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

As the largest global supplier of drugs and producer of 60% of the world’s vaccines, India has long been known as the “pharmacy of the world”.

And as the hunt for a covid vaccine is gaining momentum the country is playing a strategic and central role in it. Today Covaxin, the vaccine candidate developed by Bharat Biotech India Limited (BBIL) in collaboration with Indian Council of Medical Research (ICMR), has received approvals from India’s drug control authority, Drugs Controller General of India (DCGI's) Expert Committee for the initiation of the final and Phase III clinical trials.

According to the news reports, India’s government has set aside about 500 billion rupees ($7 billion) to vaccinate the world’s most populous country after China against the coronavirus, according to people with knowledge of the matter.

Prime Minister Narendra Modi’s administration estimates an all-in cost of about $6-$7 per person in the nation of 1.3 billion, the people said, asking not to be identified as the details are private.&nbsp;

In India, the number of daily confirmed cases has dropped but this is not the time to let your guard down. Prime Minister Narendra Modi reiterated the message a few days ago. He urged caution ahead of the festival season until we find a vaccine, the mask is our best bet. Keep it on, and stay safe.

(With inputs from agencies)

Several countries are now engaged in initiatives aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines.

Several countries are now engaged in initiatives aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines. Older adults may be most vulnerable to the coronavirus, but ending the pandemic will require vaccinating children, too. Last week, Pfizer Inc. received permission to test its vaccine in U.S. kids as young as 12, one of only a handful of attempts around the world to start exploring if any experimental shots being pushed for adults also can protect children. × As the largest global supplier of drugs and producer of 60% of the world’s vaccines, India has long been known as the “pharmacy of the world”. And as the hunt for a covid vaccine is gaining momentum the country is playing a strategic and central role in it. Today Covaxin, the vaccine candidate developed by Bharat Biotech India Limited (BBIL) in collaboration with Indian Council of Medical Research (ICMR), has received approvals from India’s drug control authority, Drugs Controller General of India (DCGI's) Expert Committee for the initiation of the final and Phase III clinical trials. According to the news reports, India’s government has set aside about 500 billion rupees ($7 billion) to vaccinate the world’s most populous country after China against the coronavirus, according to people with knowledge of the matter. Prime Minister Narendra Modi’s administration estimates an all-in cost of about $6-$7 per person in the nation of 1.3 billion, the people said, asking not to be identified as the details are private. In India, the number of daily confirmed cases has dropped but this is not the time to let your guard down. Prime Minister Narendra Modi reiterated the message a few days ago. He urged caution ahead of the festival season until we find a vaccine, the mask is our best bet. Keep it on, and stay safe. (With inputs from agencies)

Gravitas: Coronavirus exit strategy depends on getting vaccine to whole world

The University of&nbsp;Oxford's Brazilian trial of its vaccine candidate will continue after the death of a volunteer, the university said on Wednesday, adding an independent review had revealed no safety concerns.

"Following careful assessment of this case in Brazil, there have been no concerns about the safety of the clinical trial and the independent review in addition to the Brazilian regulator have recommended that the trial should continue," a spokesman for the university said in a statement.

It is the first death reported in the various coronavirus vaccine trials taking place worldwide.

Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from Covid-19.

Brazilian newspaper Globo and international news agency Bloomberg said he was in the control group and had received a placebo rather than the test vaccine, citing sources close to the trials.

"Following careful assessment of this case in Brazil, there have been no concerns about the safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue,"&nbsp;Oxford&nbsp;said in a statement.

AstraZeneca said medical confidentiality meant it could not give details on any individual volunteer, but that independent review had "not led to any concerns about the continuation of the ongoing study."

Brazil's national health regulator, Anvisa, confirmed it had been notified of the case on October 19.

The D'Or Teaching and Research Institute (IDOR), which is helping organize the tests in Brazil, said the independent review had "raised no doubts about the safety of the study, and recommended it continue."

Oxford&nbsp;and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness.

Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.

Half the volunteers in the final-stage clinical trial -- a double-blind, randomized, controlled study -- receive a placebo, IDOR said.

Around 8,000 volunteers have been vaccinated so far in Brazil, and more than 20,000 worldwide, it said.

Study participants must be doctors, nurses, or other health sector workers who come into regular contact with the virus.

The deceased volunteer was a young doctor who had been treating Covid-19 patients since March in the emergency rooms and intensive care units at two hospitals in Rio de Janeiro, Globo said.

He graduated from medical school last year, and was in good health prior to contracting the disease, family and friends told the newspaper.

The University of Oxford's Brazilian trial of its vaccine candidate will continue after the death of a volunteer, the university said on Wednesday, adding an independent review had revealed no safety concerns.

The University of Oxford's Brazilian trial of its vaccine candidate will continue after the death of a volunteer, the university said on Wednesday, adding an independent review had revealed no safety concerns. "Following careful assessment of this case in Brazil, there have been no concerns about the safety of the clinical trial and the independent review in addition to the Brazilian regulator have recommended that the trial should continue," a spokesman for the university said in a statement. It is the first death reported in the various coronavirus vaccine trials taking place worldwide. Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from Covid-19. Brazilian newspaper Globo and international news agency Bloomberg said he was in the control group and had received a placebo rather than the test vaccine, citing sources close to the trials. "Following careful assessment of this case in Brazil, there have been no concerns about the safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue," Oxford said in a statement. AstraZeneca said medical confidentiality meant it could not give details on any individual volunteer, but that independent review had "not led to any concerns about the continuation of the ongoing study." Brazil's national health regulator, Anvisa, confirmed it had been notified of the case on October 19. The D'Or Teaching and Research Institute (IDOR), which is helping organize the tests in Brazil, said the independent review had "raised no doubts about the safety of the study, and recommended it continue." Oxford and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness. Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine. Half the volunteers in the final-stage clinical trial -- a double-blind, randomized, controlled study -- receive a placebo, IDOR said. Around 8,000 volunteers have been vaccinated so far in Brazil, and more than 20,000 worldwide, it said. Study participants must be doctors, nurses, or other health sector workers who come into regular contact with the virus. The deceased volunteer was a young doctor who had been treating Covid-19 patients since March in the emergency rooms and intensive care units at two hospitals in Rio de Janeiro, Globo said. He graduated from medical school last year, and was in good health prior to contracting the disease, family and friends told the newspaper.

Oxford's Brazil vaccine trial to continue even after volunteer's death

Five people have died after getting flu shots in South Korea in the past week, authorities said, raising concerns over the vaccine's safety just as the seasonal inoculation programme is expanded to head off potential COVID-19 complications.

Authorities said there was no reason to believe the deaths were linked to the vaccine but an investigation, including post mortems, was underway.

"It makes it hard for us to put out a categorical statement," Vice Health Minister Kim Gang-lip told a briefing on Wednesday about the deaths, which include a 17-year-old boy and a man in his 70s.

Coming just weeks after the rollout of the national vaccine programme was suspended over safety worries, the deaths have dominated headlines in South Korea.

Officials last month announced plans to procure 20 per cent&nbsp;more flu vaccines for the winter than the previous year to inoculate 30 million people in a bid to prevent the health system being overloaded by patients with flu and COVID-19 exposure.

However, the start of a free jab programme for around 19 million eligible people was suspended for three weeks after it was discovered that some 5 million doses, which need to be refrigerated, had been exposed to room temperature while being transported to a medical facility.

Boosting public trust in vaccines has become a major global challenge this year, as some countries rush to approve experimental COVID-19 vaccines before full safety and efficacy studies have been completed.

South Korea's flu vaccines are supplied by different drugmakers, including LG Chem Ltd and Boryung Biopharma Co. Ltd., a unit of Boryung Pharm Co. Ltd.. A Boryung official told Reuters the company was aware of the reported deaths, but had no immediate comment. LG Chem said the company would follow government advice.

A 17-year-old boy who died on Friday was the first death noted by officials to follow receipt of the vaccine. The boy died two days after receiving the flu shot in Incheon, near the capital Seoul.

A man in his 70s, who had Parkinson's disease and arrhythmia, was the most recent case. He died in Daegu on Wednesday, a day after receiving the flu vaccine. Daegu officials said the man had received vaccines since 2015 with no prior adverse reactions.

Officials said 8.3 million people have been inoculated with the free flu vaccine since it resumed on Oct. 13, with around 350 cases of adverse reactions reported. The highest number of deaths linked to the seasonal flu vaccination was six in 2005, according to Yonhap news agency.

Even before the coronavirus pandemic, trust in vaccines was a growing challenge for public health bodies. The World Health Organization named vaccine hesitancy as one of the top 10 global health threats for last year.

In South Korea, a poll earlier this month found that 62% of 2,548 respondents in Gyeonggi province, near Seoul, would not get vaccinated against COVID-19, even if a vaccine is approved, until all safety questions are fully answered.

Five people have died after getting flu shots in South Korea in the past week, authorities said, raising concerns over the vaccine's safety just as the seasonal inoculation programme is expanded to head off potential COVID-19 complications.

Five people have died after getting flu shots in South Korea in the past week, authorities said, raising concerns over the vaccine's safety just as the seasonal inoculation programme is expanded to head off potential COVID-19 complications. Authorities said there was no reason to believe the deaths were linked to the vaccine but an investigation, including post mortems, was underway. "It makes it hard for us to put out a categorical statement," Vice Health Minister Kim Gang-lip told a briefing on Wednesday about the deaths, which include a 17-year-old boy and a man in his 70s. Coming just weeks after the rollout of the national vaccine programme was suspended over safety worries, the deaths have dominated headlines in South Korea. Officials last month announced plans to procure 20 per cent more flu vaccines for the winter than the previous year to inoculate 30 million people in a bid to prevent the health system being overloaded by patients with flu and COVID-19 exposure. However, the start of a free jab programme for around 19 million eligible people was suspended for three weeks after it was discovered that some 5 million doses, which need to be refrigerated, had been exposed to room temperature while being transported to a medical facility. Boosting public trust in vaccines has become a major global challenge this year, as some countries rush to approve experimental COVID-19 vaccines before full safety and efficacy studies have been completed. South Korea's flu vaccines are supplied by different drugmakers, including LG Chem Ltd and Boryung Biopharma Co. Ltd., a unit of Boryung Pharm Co. Ltd.. A Boryung official told Reuters the company was aware of the reported deaths, but had no immediate comment. LG Chem said the company would follow government advice. A 17-year-old boy who died on Friday was the first death noted by officials to follow receipt of the vaccine. The boy died two days after receiving the flu shot in Incheon, near the capital Seoul. A man in his 70s, who had Parkinson's disease and arrhythmia, was the most recent case. He died in Daegu on Wednesday, a day after receiving the flu vaccine. Daegu officials said the man had received vaccines since 2015 with no prior adverse reactions. Officials said 8.3 million people have been inoculated with the free flu vaccine since it resumed on Oct. 13, with around 350 cases of adverse reactions reported. The highest number of deaths linked to the seasonal flu vaccination was six in 2005, according to Yonhap news agency. Even before the coronavirus pandemic, trust in vaccines was a growing challenge for public health bodies. The World Health Organization named vaccine hesitancy as one of the top 10 global health threats for last year. In South Korea, a poll earlier this month found that 62% of 2,548 respondents in Gyeonggi province, near Seoul, would not get vaccinated against COVID-19, even if a vaccine is approved, until all safety questions are fully answered.

Five South Koreans die after getting flu shots, sparking vaccine fears

Johnson & Johnson has temporarily halted its Covid-19 vaccine trial because one of its participants became sick. "We have temporarily paused further dosing in all our Covid-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant," the company said in a statement.

Johnson & Johnson halts COVID-19 vaccine trial as participant falls ill

Johnson & Johnson said Monday it had temporarily halted its Covid-19 vaccine trial because one of its participants had become sick

Johnson & Johnson pauses Covid vaccine trial as participant falls ill

A vaccine against COVID-19 may be ready by year-end, the head of the World Health Organization (WHO) said on Tuesday, without elaborating.

'There Is Hope' COVID-19 Vaccine May Be Ready By Year-End, says WHO Chief

After promising 100,000 free vaccine doses, China is refusing to even carry out vaccine trials in Bangladesh. The Chinese company now wants Bangladesh to fund the trials too.

Gravitas: Chinese company refuses to honour vaccine deal with Bangladesh

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial.

The measure comes after&nbsp;Russian Deputy Communications Minister Alexei Volin noted that&nbsp;journalists are a part of&nbsp;a ''high risk group'' that are contracting the novel virus.

Russia&nbsp;began vaccinating members of the general public seen at high risk of coronavirus infection earlier this month, while separately launching a large-scale trial. So far about 400 people have received the jabs under that scheme, the health ministry said this week.

Also see:&nbsp;<a href="https://www.wionews.com/photos/all-you-want-to-know-about-russias-coronavirus-vaccine-sputnik-v-319775">All you want to know about Russia's coronavirus vaccine 'Sputnik V'</a>

The government last month published a list of jobs considered high risk, which included health workers, journalists and teachers.

With hundreds of potential COVID-19 vaccines in various stages of development around the world,&nbsp;Russia&nbsp;was the first country to license its vaccine for public use and alongside China has been deploying the shots before full efficacy trials are complete.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/russias-second-covid-19-vaccine-trials-complete-epivaccorona-331610/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Also see:&nbsp;<a href="https://www.wionews.com/photos/after-russia-these-covid-19-vaccines-set-to-unveil-soon-319760">After Russia, these COVID-19 vaccines set to unveil soon!</a>

Two journalists at the state-run RIA news agency and two at the&nbsp;Russian state television holding company VGTRK, which operates&nbsp;Russia-1 and&nbsp;Russia-24 news channels, said they had been offered a COVID-19 shot on a voluntary basis.

One of the RIA journalists said his impression was that the majority of his colleagues had declined the offer. One of the VGTRK journalists also said many of his colleagues declined.

The RIA news agency confirmed the inoculation program. "We granted employees who constantly work from the office (not remotely), at events, and in the field, the option to receive a Sputnik V vaccination," it said in a statement.

RIA did not say how many employees received the vaccine and VGTRK did not respond to a request for comment. Both companies employ hundreds of people.

At RIA and VGTRK headquarters in Moscow, media workers who spoke to Reuters said they had a basic medical check-up and coronavirus PCR and antibody tests.

In an interview, the chief scientist behind the vaccine's development said people vaccinated outside of a trial undergo a less rigorous medical examination, though they can submit additional health data via an online platform.

At the time of its registration, the vaccine had been tested officially on fewer than 100 volunteers as part of early-stage clinical trials. Late stage trials began last month, with the first volunteer of a 40,000-strong cohort vaccinated on September&nbsp;9.

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial.

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial. The measure comes after Russian Deputy Communications Minister Alexei Volin noted that journalists are a part of a ''high risk group'' that are contracting the novel virus. Russia began vaccinating members of the general public seen at high risk of coronavirus infection earlier this month, while separately launching a large-scale trial. So far about 400 people have received the jabs under that scheme, the health ministry said this week. Also see: All you want to know about Russia's coronavirus vaccine 'Sputnik V' The government last month published a list of jobs considered high risk, which included health workers, journalists and teachers. With hundreds of potential COVID-19 vaccines in various stages of development around the world, Russia was the first country to license its vaccine for public use and alongside China has been deploying the shots before full efficacy trials are complete. Also see: After Russia, these COVID-19 vaccines set to unveil soon! Two journalists at the state-run RIA news agency and two at the Russian state television holding company VGTRK, which operates Russia-1 and Russia-24 news channels, said they had been offered a COVID-19 shot on a voluntary basis. One of the RIA journalists said his impression was that the majority of his colleagues had declined the offer. One of the VGTRK journalists also said many of his colleagues declined. The RIA news agency confirmed the inoculation program. "We granted employees who constantly work from the office (not remotely), at events, and in the field, the option to receive a Sputnik V vaccination," it said in a statement. RIA did not say how many employees received the vaccine and VGTRK did not respond to a request for comment. Both companies employ hundreds of people. At RIA and VGTRK headquarters in Moscow, media workers who spoke to Reuters said they had a basic medical check-up and coronavirus PCR and antibody tests. In an interview, the chief scientist behind the vaccine's development said people vaccinated outside of a trial undergo a less rigorous medical examination, though they can submit additional health data via an online platform. At the time of its registration, the vaccine had been tested officially on fewer than 100 volunteers as part of early-stage clinical trials. Late stage trials began last month, with the first volunteer of a 40,000-strong cohort vaccinated on September 9.

Russian state journalists among first to receive Sputnik V vaccine

Russia is considering a 'tech transfer' of its Sputnik V vaccine to India. Reportedly, this will be a partnership to develop, manufacture and supply the vaccine.

Gravitas: An India-Russia alliance for Wuhan virus vaccine?

As many as 44 per cent of Greeks said they would not take a <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccine for the novel coronavirus</a>, a poll published on Sunday revealed.&nbsp;

According to the study published in To Vima weekly, forty-four per cent of participants said they would not take the COVID-19 vaccine even if it is freely available and duly approved.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/90-of-chinas-sinovac-employees-families-took-coronavirus-vaccine-325534">90% of China's Sinovac employees, families took coronavirus vaccine</a>

It said the vaccine refusal rate is 56 per cent in the age group of 45-54 and 54 per cent among 17-34 category.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/uncertainty-over-long-term-immune-response-has-implications-for-vaccine-efficacy-experts-325524">Uncertainty over long-term immune response has implications for vaccine efficacy: Experts</a>

The study that was carried out by Greek company Metron Analysis and included 1,000 respondents also found that nearly 17 per cent people oppose wearing masks in public spaces.&nbsp;

The Greek government has already said that the vaccine to treat the deadly virus would not be mandatory, but will be "strongly recommended."

Greece has so far handled the virus much better than other European countries with over 11,500 infections and 284 deaths.

However, half of the total number of infections were recorded in August, suggesting that reopening of economy, borders and resumption of large gatherings have led to a sharp rise in cases.&nbsp; 
&nbsp;

As many as 44 per cent of Greeks said they would not take a vaccine for the novel coronavirus, a poll published on Sunday revealed. According to the study published in To Vima weekly, forty-four per cent of participants said they would not take the COVID-19 vaccine even if it is freely available and duly approved.

As many as 44 per cent of Greeks said they would not take a vaccine for the novel coronavirus, a poll published on Sunday revealed. According to the study published in To Vima weekly, forty-four per cent of participants said they would not take the COVID-19 vaccine even if it is freely available and duly approved. Also read | 90% of China's Sinovac employees, families took coronavirus vaccine It said the vaccine refusal rate is 56 per cent in the age group of 45-54 and 54 per cent among 17-34 category. Also read | Uncertainty over long-term immune response has implications for vaccine efficacy: Experts The study that was carried out by Greek company Metron Analysis and included 1,000 respondents also found that nearly 17 per cent people oppose wearing masks in public spaces. The Greek government has already said that the vaccine to treat the deadly virus would not be mandatory, but will be "strongly recommended." Greece has so far handled the virus much better than other European countries with over 11,500 infections and 284 deaths. However, half of the total number of infections were recorded in August, suggesting that reopening of economy, borders and resumption of large gatherings have led to a sharp rise in cases.

44% of people in Greece to skip coronavirus vaccine: Study

India yesterday set a record when it reported 78,761 new infections in 24 hours -- the world's highest single-day rise

India: 78,512 cases and 971 deaths in 24 hours

Potential coronavirus vaccine makers have seen a massive rise in their company's stocks if the drug has reported positive news to fight the deadly virus. And one such individual is Jiang Rensheng, chairman of Chongqing Zhifei Biological Products Co, whose wealth has seen a massive rise, making him enter.the club of China's ten richest people.&nbsp;

The pharma company's shares have jumped 80 per cent since China's drug regulator gave green signal to clinical human trials of a potential vaccine to treat coronavirus.&nbsp;

Also read | <a href="https://www.wionews.com/world/fauci-expects-tens-of-millions-of-coronavirus-vaccine-doses-at-start-of-2021-318487">Fauci expects tens of millions of coronavirus vaccine doses at start of 2021</a>

This development has led to Jiang seeing his wealth soar up to $19.3 billion, according to the Bloomberg Billionaires Index.&nbsp;

Also read | <a href="https://www.wionews.com/world/us-to-pay-johnson-johnson-over-1-bn-for-100-mn-doses-of-its-potential-coronavirus-vaccine-318477">US to pay Johnson &amp; Johnson over $1 bn for 100 mn doses of its potential coronavirus vaccine</a>

In July alone, his net worth more than doubled, which is the fastest among the world's 500 richest people, and jumped by $14.3 billion in 2019.&nbsp;

In a speech at his alma mater in May 2019, Jiang said social responsibility, not wealth is the true measure of success, reported Bloomberg.&nbsp;

Chongqing Zhifei sells vaccines for diseases, including flu and meningitis and is China's sole marketer of a Merck &amp; Co. treatment to avoid cervical cancer.

In the first six months of this year, Zhifei's net income rose up to 1.5 billion yuan or 30 per cent from last year.&nbsp;

Interestingly, the pharma company has produced at least another billionaire this year.&nbsp;

Wu Guanjiang, a former director of Chongqing Zhifei, has a stake of 8 per cent stake in the company, which doubled his fortune to $4.5 billion in 2020.&nbsp;

Potential coronavirus vaccine makers have seen a massive rise in their company's stocks if the drug has reported positive news to fight the deadly virus. And one such individual is Jiang Rensheng, chairman of Chongqing Zhifei Biological Products Co, whose wealth has seen a massive rise, making him enter.

Potential coronavirus vaccine makers have seen a massive rise in their company's stocks if the drug has reported positive news to fight the deadly virus. And one such individual is Jiang Rensheng, chairman of Chongqing Zhifei Biological Products Co, whose wealth has seen a massive rise, making him enter.the club of China's ten richest people. The pharma company's shares have jumped 80 per cent since China's drug regulator gave green signal to clinical human trials of a potential vaccine to treat coronavirus. Also read | Fauci expects tens of millions of coronavirus vaccine doses at start of 2021 This development has led to Jiang seeing his wealth soar up to $19.3 billion, according to the Bloomberg Billionaires Index. Also read | US to pay Johnson & Johnson over $1 bn for 100 mn doses of its potential coronavirus vaccine In July alone, his net worth more than doubled, which is the fastest among the world's 500 richest people, and jumped by $14.3 billion in 2019. In a speech at his alma mater in May 2019, Jiang said social responsibility, not wealth is the true measure of success, reported Bloomberg. Chongqing Zhifei sells vaccines for diseases, including flu and meningitis and is China's sole marketer of a Merck & Co. treatment to avoid cervical cancer. In the first six months of this year, Zhifei's net income rose up to 1.5 billion yuan or 30 per cent from last year. Interestingly, the pharma company has produced at least another billionaire this year. Wu Guanjiang, a former director of Chongqing Zhifei, has a stake of 8 per cent stake in the company, which doubled his fortune to $4.5 billion in 2020.

China: Vaccine tycoon has world's fastest growing fortune

corona-vaccine

Corona Vaccine, News on Corona Vaccine, stories on Corona Vaccine, articles on Corona Vaccine, Corona Vaccine stories at Wion, Corona Vaccine news, Corona Vaccine latest news